Product Detailed Description

liposomal Calcium Alpha-Ketoglutarate 70% — High Bioavailability Cellular Energy Supplement

Product Overview

Liposomal Calcium Alpha-Ketoglutarate 70% is a premium-grade dietary supplement ingredient delivering calcium alpha-ketoglutarate (Ca-AKG) in an advanced liposomal delivery system. Alpha-ketoglutarate (AKG, also known as 2-oxoglutarate or 2-oxopentanedioic acid) is a dicarboxylic acid with the molecular formula C₅H₆O₅ and a molecular weight of 146.10 g/mol. It is a key intermediate in the TCA cycle (Krebs cycle), the central metabolic pathway for cellular energy production.

Ca-AKG is the calcium salt form of AKG, preferred in supplement applications for its enhanced stability and bioavailability compared to free AKG. AKG serves as a critical junction point in metabolism with three primary functions: it acts as an energy donor in the TCA cycle, serves as a nitrogen transporter linking carbohydrate and nitrogen metabolism, and functions as a precursor for amino acid biosynthesis including glutamate and glutamine. Beyond its metabolic roles, AKG is a key signaling molecule that regulates gene expression through epigenetic mechanisms, including the modulation of DNA and histone demethylation via TET dioxygenases.

Why Liposomal Technology?

Conventional Ca-AKG presents significant formulation challenges. The primary reasons for poor oral bioavailability include its hydrophilic and charged nature, which limits passive diffusion across intestinal epithelial cell membranes, as well as its rapid metabolism in the gut and liver with a plasma half-life of less than 5 minutes. Following oral administration, AKG is primarily taken up by the liver and rapidly converted to other metabolites, limiting its systemic availability and distribution to peripheral tissues.

Liposomal encapsulation provides three critical advantages:

1. Digestive Protection — The phospholipid bilayer shields AKG from gastric acid degradation and premature metabolism during digestive transit, preserving its intact molecular structure until reaching optimal absorption sites in the small intestine. Conventional pills and powders show limited AKG absorption, while the liposomal structure creates a protective layer around nutrients, keeping them away from gastric acid and maintaining optimal bioavailability.

2. Enhanced Cellular Uptake — liposomes fuse directly with intestinal cell membranes, facilitating efficient cellular delivery and bypassing the charged-dicarboxylate membrane permeability limitation. This delivery system enables enhanced absorption via lipid-mediated pathways, complementing the organic acid transport mechanisms utilized by AKG.

3. Mitochondrial Targeting — AKG's primary metabolic activity occurs within mitochondria. Liposomal delivery shields AKG from premature degradation and facilitates direct delivery to these organelles, where it participates in TCA cycle reactions and serves as a cofactor for epigenetic enzymes.

Product Specifications

Key Features

• High Purity — Standardized to ≥70% calcium alpha-ketoglutarate by HPLC, ensuring consistent active content.

• Liposomal Enhancement — Sunflower phospholipid bilayer encapsulation protects AKG from gastric degradation and enhances intestinal absorption, addressing the charged-dicarboxylate membrane permeability limitation and sub-5-minute plasma half-life of native AKG.

• TCA Cycle Energy Support — AKG is a central intermediate in the TCA cycle, supporting efficient ATP production and cellular Energy Metabolism.

• Epigenetic Regulation — AKG serves as an obligate cofactor for TET dioxygenases and JmjC-domain-containing histone demethylases, playing a central role in epigenetic maintenance and gene expression regulation.

• Clinically Validated for Biological Age — A clinical study using 1 g/day Ca-AKG with vitamins A and D for an average of 7 months demonstrated an average reduction in biological age of approximately 8 years in healthy individuals aged 40–65.

• Ongoing Clinical Research — The ABLE trial (Alpha-ketoglutarate Supplementation and BiologicaL agE) is a double-blind, placebo-controlled randomized trial evaluating 1 g/day sustained-release Ca-AKG over 6 months in 120 generally healthy adults aged 40–60 with higher biological than chronological age.

• GRAS Status — Ca-AKG is Generally Recognized As Safe (GRAS) under U.S. FDA guidelines and is included in the U.S. list of old dietary ingredients, allowing lawful use as a food ingredient.

• Water-Dispersible — Suitable for capsules, tablets, powder drink mixes, and functional beverages.

• Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.

Application & Formulation Guidance

Recommended Dosage

Clinical studies have evaluated Ca-AKG across a range of doses. The ABLE trial (Alpha-ketoglutarate Supplementation and BiologicaL agE) is evaluating 1 g/day sustained-release Ca-AKG over 6 months in 120 generally healthy adults aged 40–60 with higher biological than chronological age. A separate randomized, double-blind, placebo-controlled trial in adults aged 40–75 is evaluating 2 g/day Ca-AKG over 12 weeks to assess changes in PhenoAge, a measure of biological aging, as well as bone health, physical strength, body composition, and metabolic markers. Several clinical trials using Ca-AKG in hemodialysis patients found it to be safe at doses up to 4.5 g/day. For general metabolic and anti-aging support, 1 g daily is commonly used. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability.

Shipping & Lead Time

• Stock Orders: 3–5 business days after payment confirmation.

• Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.

• Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.

• Coverage: Worldwide shipping, including remote areas.